Jeong S. Moon

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 90 publications

Efficacy and Safety of Fexuprazan-Based Modified High-Dose Dual Therapy for Helicobacter pylori Eradication: A Randomized Clinical Trial.

Efficacy and Safety of Fexuprazan-Based Modified High-Dose Dual Therapy for Helicobacter pylori Eradication: A Randomized Clinical Trial.

Journal: Helicobacter

Published: February 18, 2026

A Phase III, Randomized, Double-Blind, Active-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Tegoprazan for the Prevention of Peptic Ulcer in Patients on Continuous Long-Term Treatment with Nonsteroidal Anti-Inflammatory Drugs.

A Phase III, Randomized, Double-Blind, Active-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Tegoprazan for the Prevention of Peptic Ulcer in Patients on Continuous Long-Term Treatment with Nonsteroidal Anti-Inflammatory Drugs.

Journal: Gut and liver

Published: February 04, 2026

Laparoscopic and endoscopic cooperative surgery: current status and clinical applications.

Laparoscopic and endoscopic cooperative surgery: current status and clinical applications.

Journal: Clinical endoscopy

Published: January 01, 2026

Tegoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Phase III Multicenter Randomized Clinical Trial.

Tegoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Phase III Multicenter Randomized Clinical Trial.

Journal: Helicobacter

Published: October 14, 2025

Randomized, Double-Blind, Active-Controlled, Parallel, Phase 3 Clinical Trial for Evaluating the Efficacy and Safety of Zastaprazan in Patients with Gastric Ulcers.

Randomized, Double-Blind, Active-Controlled, Parallel, Phase 3 Clinical Trial for Evaluating the Efficacy and Safety of Zastaprazan in Patients with Gastric Ulcers.

Journal: Gut and liver

Published: July 09, 2025

Practice Guidelines for the Diagnosis and Treatment of Subepithelial Lesion Observed in Upper Gastrointestinal Endoscopy.

Practice Guidelines for the Diagnosis and Treatment of Subepithelial Lesion Observed in Upper Gastrointestinal Endoscopy.

Journal: Journal of gastroenterology and hepatology

Published: June 09, 2025

Programmable Argonaute-mediated single-nucleotide variant sequencing of cell-free DNA for multi-cancer early detection.

Programmable Argonaute-mediated single-nucleotide variant sequencing of cell-free DNA for multi-cancer early detection.

Journal: Nature communications

Published: April 15, 2025

Practice Guidelines for the Diagnosis and Treatment of Subepithelial Lesions Observed in Upper Gastrointestinal Endoscopy.

Practice Guidelines for the Diagnosis and Treatment of Subepithelial Lesions Observed in Upper Gastrointestinal Endoscopy.

Journal: The Korean journal of helicobacter and upper gastrointestinal research

Published: March 11, 2025

CRISPR anti-tag-mediated room-temperature RNA detection using CRISPR/Cas13a.

CRISPR anti-tag-mediated room-temperature RNA detection using CRISPR/Cas13a.

Journal: Nature communications

Published: January 15, 2025

Evaluation of the Efficacy and Safety of a Dual Delayed-Release Formulation of 10-mg Esomeprazole in Patients with Gastric Erosions: A Multicenter, Randomized, Double-Blind, Active-Control, Phase III Study.

Evaluation of the Efficacy and Safety of a Dual Delayed-Release Formulation of 10-mg Esomeprazole in Patients with Gastric Erosions: A Multicenter, Randomized, Double-Blind, Active-Control, Phase III Study.

Journal: Gut and liver

Published: August 28, 2024

Efficacy and safety of rebamipide/nizatidine in patients with erosive gastritis: A randomized, multicenter, phase 4 study.

Efficacy and safety of rebamipide/nizatidine in patients with erosive gastritis: A randomized, multicenter, phase 4 study.

Journal: World journal of gastroenterology

Published: June 20, 2024

Efficacy and safety of HIP1601 (dual delayed-release esomeprazole) 40 mg in erosive esophagitis compared to HGP1705 (delayed-release esomeprazole) 40 mg: a multicenter, randomized, double-blind, non-inferiority study.

Efficacy and safety of HIP1601 (dual delayed-release esomeprazole) 40 mg in erosive esophagitis compared to HGP1705 (delayed-release esomeprazole) 40 mg: a multicenter, randomized, double-blind, non-inferiority study.

Journal: BMC gastroenterology

Published: August 30, 2023

Showing 1-12 of 90

Last Updated: 09/26/2026